Avarieux
back to explore
Arvinas Inc logo

ARVN

Arvinas Inc
NASDAQ NMS - GLOBAL MARKET· Pharmaceuticals· US· IPO 2018-09-27
$9.32
-0.27 (-2.77%)
last quote
Want the full multi-source brief on ARVN?
The agent pulls regulatory filings, news flow, prediction-market pricing, and macro context — then synthesizes what's not yet in the price.
open in agent
Today
Open
$9.32
High
$9.69
Low
$9.31
Previous close
$9.59
Fundamentals
Market cap
$585.53M
P/E (TTM)
62.96x
P/S (TTM)
1.85x
P/B
1.76x
Gross margin
—
Operating margin
-5.72%
Net margin
2.94%
Rev growth (YoY)
-15.05%
EPS growth (YoY)
—
ROE
1.91%
52W high
$14.51
52W low
$6.97
Beta
1.80x
Industry peers
by market cap
COLL-1.85%PHAT-1.84%CRMD-1.05%AQST-1.75%CTNM+2.32%EOLS-0.72%ZVRA+1.30%VREO.CN
Upcoming earnings
next 30 days
2026-11-03in 60 days
Q3 2026EPS est $-0.87Rev est $23.6M
Recent SEC filings
CIK 1655759filing-language history →
S-82026-08-31
403 KB
SCHEDULE 13G/A2026-08-14
30 KB
1442026-08-04
6 KB
10-Q2026-08-04reports 2026-06-30
32,268 KB
8-K2026-08-04
352 KB
1442026-07-09
6 KB
Recent news
2026-08-27 → 2026-09-03
SeekingAlpha · 6d
Arvinas: Veppanu Approval Underlines Degrader Platform Promise - I'm Bullish
Arvinas, Inc. is upgraded to a Buy, underpinned by Veppanu’s FDA approval and a robust PROTAC platform. Learn more about ARVN stock here.
SEC EDGAR Yahoo Finance TradingView Company website
This is the free preview

The agent layer adds regulatory-language drift detection, cross-venue prediction-market signals, macro overlays, programmable alert rules, overnight briefs, and a grounding verifier on every claim. 7-day Pro trial, no card required.

Start the trial